Immix Biopharma highlights NXC-201 CAR-T data in relapsed/refractory AL amyloidosis trial presentation

PUBT · 3d ago
Immix Biopharma highlights NXC-201 CAR-T data in relapsed/refractory AL amyloidosis trial presentation
  • Immix investor presentation highlighted NXC-201 BCMA CAR-T in relapsed/refractory AL amyloidosis, a setting with no FDA-approved therapies.
  • NXC-201 posted a 95% complete hematologic response rate in NEXICART-2 data presented at ASH 2025 with a May 2026 update.
  • NEXICART-2 is an open-label, single-arm, multi-site phase 1/2 study with 45 patients; enrollment completed in March 2026.
  • Program timeline calls for a planned BLA submission following 1-year follow-up for all 45 patients, with the next update in late September 2026.
  • Commercial launch plan targets end of 2027; presentation cites expected pricing of USD 588K, referencing 2026 Carvykti BCMA CAR-T pricing.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immix Biopharma Inc. published the original content used to generate this news brief on September 02, 2026, and is solely responsible for the information contained therein.